The upcoming report from Integer (ITGR) is expected to reveal quarterly earnings of $1.24 per share, indicating an increase of 8.8% compared to the year-ago period. Analysts forecast revenues of $438.15 million, representing an increase of 9.5% year over year.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Before a company announces it ...

Integer (ITGR) came out with quarterly earnings of $1.30 per share, beating the Zacks Consensus Estimate of $1.24 per share. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.84%. A quarter ago, it was expected that this medical device outsource manufacturer would post earnings of $1.12 per share when it actually produced earnings of $1.14, delivering a surprise of 1.79%.Over the last four qu ...

财务业绩 - 销售增长9%至4.36亿美元，其中有机增长5%[3] - GAAP净收入增长30%至3100万美元，非GAAP调整后净收入增长17%至4500万美元[3] - GAAP营业收入增长33%至5520万美元，非GAAP调整后营业收入增长20%至7200万美元[3] - GAAP每股摊薄收益增长23.9%至0.88美元，非GAAP调整后每股收益增长14%至1.30美元[20,21] - 调整后EBITDA增长19%至9110万美元[21] - 2024年全年销售增长预期为9%至11%，调整后营业收入增长预期为14%至21%[10] - 2024年全年调整后EBITDA增长预期为15%至22%，调整后每股收益增长预期为9%至18%[10] - 公司2024年6月28日季度销售收入为436,202,000美元，同比增长9.0%[44] - 公司2024年上半年销售收入为851,007,000美元，同比增长9.3%[44] - 公司2024年6月28日季度毛利率为27.4%[44] - 公司2024年上半年毛利率为26.9%[44] - 公司2024年6月28日季度经营利润为55,186,000美元，同比增长32.8%[44] - 公司2024年上半年经营利润为94,463,000美元，同比增长24.7%[44] - 公司2024年6月28日季度调整后EBITDA为89,000,000美元[34] - 公司2024年6月28日季度调整后经营利润为72,000,000美元[34] - 公司净收入为51,754千美元，较上年同期增长39.6%[48] - 公司调整后净收入为83,651千美元，较上年同期增长24.1%[54] - 公司调整后每股摊薄收益为2.01美元，较上年同期增长0.90美元[54] - 公司调整后营业收入为134,723千美元，较上年同期增长22.8%[70] - 公司第二季度总销售额同比增长9.0%，其中医疗销售额增长9.8%[75] - 公司第二季度调整后EBITDA为76,300千美元[72] - 公司第二季度净收入为23,971千美元[71] 债务情况 - 从2023年底开始，总债务增加1.59亿美元至11.19亿美元，净总债务增加1.47亿美元至10.97亿美元[3] - 公司6月28日2024年净总债务为1,096,863千美元[79] 业务分部表现 - 心血管和神经调控业务销售分别增长11%和9%[5,6] - 先进外科、骨科和便携式医疗业务销售增长4%[7] - 医疗业务中，心血管和神经调节业务销售额增长9.3%，先进外科、骨科和便携式医疗业务销售额增长4.4%[75] 费用情况 - 公司收购和整合成本为5,858千美元，主要与业务或资产收购直接相关[60] - 公司其他一般费用包括处置固定资产的收益和损失，以及与2023年第四季度一处制造设施发生的财产损失有关的1,200千美元损失回收[61] - 公司重组和相关费用为3,308千美元，主要用于优化资源以更好地服务客户和市场、提高运营效率和能力、降低运营成本或提高盈利能力[59] - 公司遵守新的欧盟医疗器械法规的额外费用为437千美元[64] - 公司其他调整费用为588千美元，主要与某些正式战略项目相关[65] - 公司第二季度股票激励费用为5,499千美元[72] - 公司第二季度重组和相关费用为3,116千美元[72] - 公司第二季度收购和整合费用为556千美元[72] - 公司第二季度医疗器械监管费用为534千美元[72] - 公司第二季度其他调整费用为909千美元[72]

PLANO, Texas, July 01, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR) (“Integer” or the “Company”), a leading medical device contract development and manufacturing organization, today notified holders of its 2.125% Convertible Senior Notes due 2028 (the “Notes”) that the Notes are convertible, at the option of the holders (the “Conversion Option”) beginning on July 1, 2024, and ending at the close of business on September 30, 2024. The Notes are convertible into cash, up to the principal ...

PLANO, Texas, July 01, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) ("Integer" or the "Company"), a leading medical device contract development and manufacturing organization, today notified holders of its 2.125% Convertible Senior Notes due 2028 (the "Notes") that the Notes are convertible, at the option of the holders (the "Conversion Option") beginning on July 1, 2024, and ending at the close of business on September 30, 2024. The Notes are convertible into cash, up to the principal ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium also includes the Zacks Style Scores. Wha ...

PLANO, Texas, June 27, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that it plans to release financial and operational results for second quarter 2024 at 7 a.m. Central Time (CT) / 8 a.m. Eastern Time (ET) on Thursday, July 25, 2024. Following the release, Integer management will host a webcast at 8 a.m. CT / 9 a.m. ET to discuss these results. Other forward-looking and material information may also be discussed during this call. Conference call details: Date: Thursday, ...

Integer Holdings Corporation (ITGR) has been gaining from its research and product development activities. The optimism led by a solid first-quarter 2024 performance and its solid foothold in the broader MedTech space are expected to contribute further. However, healthcare industry regulations and dependence on third-party suppliers are a hurdle. In the past year, this Zacks Rank #3 (Hold) stock has gained 42.6% compared with the 4.5% rise of the industry and the S&P 500’s 16.5% growth. The renowned medical ...

PLANO, Texas, June 06, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced participation at the 2024 Truist Securities MedTech Conference, to be held June 17 – 18, 2024, in Boston. Integer President and Chief Executive Officer Joseph Dziedzic is scheduled to present as part of a fireside chat on Tuesday, June 18, at 1:55 p.m. ET. A live webcast of the presentation will be accessible und ...

PLANO, Texas, June 06, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced participation at the 2024 Truist Securities MedTech Conference, to be held June 17 – 18, 2024, in Boston. Integer President and Chief Executive Officer Joseph Dziedzic is scheduled to present as part of a fireside chat on Tuesday, June 18, at 1:55 p.m. ET. A live webcast of the presentation will be accessible und ...